Navigation Links
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer

Lugano-CH, Brussels-BE, 2 May 2013 -- A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved.

Prof Mario Campone, Principal Investigator at Institut Cancerologie de l'Ouest in Nantes, France, presented the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

"As more targeted cancer drugs are developed, the challenge is to identify which patients will benefit from individual agents," Prof Campone said. "One of the objectives of this study was to determine molecular biomarkers that predict whether a patient's cancer is sensitive to the combination of everolimus and trastuzumab compared to trastuzumab alone."

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Many patients who initially respond to trastuzumab develop resistance.

In preclinical studies, everolimus, an oral inhibitor of an important molecule called mammalian target of rapamycin (mTOR), has demonstrated an ability to reverse trastuzumab resistance. However, the mechanisms of action involved in the reversion of trastuzumab resistance are not completely understood.

"Resistance to trastuzumab may result from several molecular alterations occurring at different levels of the downstream effectors in the PI3K/AKT pathway, all of them resulting in maintenance of signal transduction," Prof Campone explains. "Therefore, using everolimus to inhibit mTOR, a major downstream effector of this pathway, can restore sensitivity to trastuzumab. In a pre-clinical model, everolimus also reverses trastuzumab resistance caused by upregulation of IGF-1R expression, an alternative signaling pathway, allowing IGF-1 to drive cell growth and proliferation."

At the IMPAKT meeting, Prof Campone's group report the first results of a clinical study and analysis of seven biomarkers in patients with early HER2-overexpressing cancers who were receiving treatment with trastuzumab alone, or everolimus plus trastuzumab.

Among the 80 patients (40 per arm), the clinical response rate was 35% in the trastuzumab arm and 45% in the patients who received both drugs. On the other hand, the pathological response rate was 43.5% among patients in the monotherapy arm, and 47.5% in the combination arm of the study.

"The conclusion of this paper in clinical practice is that the addition of everolimus to trastuzumab seems to improve the clinical response rate but not the pathologic response," Prof Campone said.

The researchers also studied a group of seven molecular markers to explore whether they could be used to predict which patients would respond to the combination of everolimus and trastuzumab. The biomarkers were p4EBP1, pS6, eIF4E, Ki67, pAKT, LKB1, and caspase 3, all of which are involved in pathways that lead to the activation of mTOR.

"None of these biomarkers was able to predict which patients would see the benefit of the two drugs," Prof Campone said. "It appears the combination of everolimus and trastuzumab is effective independently of the activation of the PI3K/AKT/mTOR pathway and without any anti-proliferative and pro-apoptotic effect."

The study provides important confirmation of the benefit of adding everolimus in this clinical setting, comments Prof Christoph Zielinski, Chairman of the Department of Medicine I at Medical University Vienna, Austria.

"This is a rather small trial with a limited number of patients, although it quite unequivocally shows that the addition of everolimus to trastuzumab leads to an increase in clinical responses in Her-2/neu overexpressing breast cancer, as compared to trastuzumab alone," he said.

"Thus, it not only adds to clinical possibilities which can be offered to patients, but also further explains the modalities of molecularly directed therapeutic manipulation in breast cancer," said Prof Zielinski. However, the limited pathologic response constitutes a clear drawback from clinical observations.

"Nevertheless this study contributes to our assumptions on the application of molecularly targeted therapies in breast cancer in particular and in malignancies in general. It also helps to move to an era where the targeting of multiple molecular structures (like here with trastuzumab and everolimus) leads to ameliorated results by 'hitting' multiple growth-regulating mechanisms, but also avoiding treatment resistance which continues to be a major challenge in cancer treatment."


Contact: Vanessa Pavinato
European Society for Medical Oncology

Related biology news :

1. Study reveals magnitude of variation in gene expression measurements within breast cancers
2. Study opens new prospects for developing new targeted therapies for breast cancer
3. Breast cancer heterogeneity no barrier to predictive testing, study shows
4. BUSM study shows positive impact of mind-body course on well-being of medical students
5. Study finds possible alternative to bariatric weight loss surgery
6. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
7. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
8. University of Houston engineering professor awarded grant to study melanoma treatment
9. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
10. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
11. Study led by NUS scientists reveals escalating cost of forest conservation
Post Your Comments:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology: